Novozymes ended a turbulent FY 15 on an expectedly soft note with Q4 15 results coming in boardly in line with the muted market and our expectations. Q4 sales were up 2% yoy (organic growth rates, unless otherwise specified) to DKK3.5bn (Q3: +3%), as continued momentum in Agriculture & Feed (+18%; Q3: +20%) and Food & Beverages (+4%; Q3: +6%) as well as recovery in Technical & Pharma (+21%; Q3: -8%) partially offset the weak performance of Bioenergy (-15%; Q3: -6%). Forex benefits
25 Jan 2016
Crude reality check triggers FY 17-20 downgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Crude reality check triggers FY 17-20 downgrade
Novonesis A/S Class B (NZYM:WBO) | 0 0 2.6% | Mkt Cap: 80,754m
- Published:
25 Jan 2016 -
Author:
Jyoti Prakash -
Pages:
3
Novozymes ended a turbulent FY 15 on an expectedly soft note with Q4 15 results coming in boardly in line with the muted market and our expectations. Q4 sales were up 2% yoy (organic growth rates, unless otherwise specified) to DKK3.5bn (Q3: +3%), as continued momentum in Agriculture & Feed (+18%; Q3: +20%) and Food & Beverages (+4%; Q3: +6%) as well as recovery in Technical & Pharma (+21%; Q3: -8%) partially offset the weak performance of Bioenergy (-15%; Q3: -6%). Forex benefits